

What is Claimed is:

1. A conjugate comprising Substance P or an analog thereof, and a protein that inhibits protein synthesis.
2. The conjugate of claim 1, wherein the conjugate comprises an analog of Substance P.
3. The conjugate of claim 1, wherein the Substance P has the amino acid sequence at the N-terminus
CYGGGGGRPKPQQFFSarLMet(0₂)-amide (SEQ ID NO. 1).
4. The conjugate of claim 1, wherein the Substance P has the amino acid sequence at the N-terminus CYGGGGGRPKPQQFFGLM-amide (SEQ ID NO. 2).
5. The conjugate of claim 1, wherein the protein is Saporin.
6. The conjugate of claim 1, wherein the protein is in a recombinant form.
- 15 7. A conjugate comprising a protein that inhibits protein synthesis and an antibody that recognizes the NK-1 receptor.
8. The conjugate of claim 1, wherein the protein is ricin A chain, gelonin, pokeweed antiviral protein, or a bacterial toxin, or any fragment thereof, that inhibits protein synthesis.
- 20 9. The conjugate of claim 1, wherein the protein is diphtheria toxin or pseudomonas aeruginosa toxin, or any fragment thereof.

10. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 1 and a pharmaceutically acceptable carrier.
11. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 2 and a pharmaceutically acceptable carrier.
5
12. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 3 and a pharmaceutically acceptable carrier.
13. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 4 and a pharmaceutically acceptable carrier.
10
14. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 8 and a pharmaceutically acceptable carrier.
15
15. A pharmaceutical composition comprising a therapeutically effective amount of the conjugate of claim 9 and a pharmaceutically acceptable carrier.
16. A method of reducing the perception of pain by a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 10 so as to reduce the perception of pain by the subject.
20
17. A method of reducing the perception of pain by a subject comprising administering to the subject an effective amount

of the pharmaceutical composition of claim 11 so as to reduce the perception of pain by the subject.

18. A method of reducing the perception of pain by a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 12 so as to reduce the perception of pain by the subject.

19. A method of reducing the perception of pain by a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 13 so as to reduce the perception of pain by the subject.

20. A method of reducing the perception of pain by a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 14 so as to reduce the perception of pain by the subject.

15 21. A method of reducing the perception of pain by a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 15 so as to reduce the perception of pain by the subject.

22. A method of selectively destroying NK-1 receptor expressing cells in a subject comprising administering to the subject an effective amount of the conjugate of claim 1 so as to selectively destroy NK-1 receptor expressing cells.

23. A method of treating a subject with cancer comprising administering to the subject an effective amount of the

pharmaceutical composition of claim 10 so as to treat the cancer.

24. A method for treating a NK-1 receptor associated disorder in a subject, which comprises administering to the subject an amount of the pharmaceutical composition of claim 10 thereby treating the disorder associated with the NK-1 receptor.